



Sheet 1 of 3

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-921 MIS:bh	SERIAL NO. 09/361,619
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Sheena M. Loosmore et al	
		FILING DATE July 27, 1999	GROUP 1644 1645

MAR 23 2000

TECH CENTER 1600/

U.S. PATENT DOCUMENTS

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
SD	5,808,024	Sep.15,98	Ken Sasaki et al			
SD	4,855,029	Aug.8,89	Chester T. Gazda et al			
SD	4,855,283	Aug.8,89	O. Lockhoff et al			
SD	4,952,496	Aug.28,90	F. W. Studier et al			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	YES	NO
SD	WO 96/34960	Nov.7,96	PCT					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SD	1. Van Hare, G.F., P.A. Shurin, C.D. Marchant, N.A. Cartelli, C.E.Johnson, D. Fulton, S. Carlin, and C.H. Kim. Acute otitis media caused by <i>Branhamella catarrhalis</i> : biology and therapy. (1987) Rev. Infect. Dis. 9:16-27.
SD	2. Chapman, A.J., D.M. Musher, S. Jonsson, J.E. Clarridge, and R.J. Wallace. 1985. Development of bactericidal antibody during <i>Branhamella catarrhalis</i> infection. J. Infect. Dis. 151:878-882.
SD	3. Hager, H., A. Verghese, S. Alvarez, and S.L. Berk. 1987. <i>Branhamella catarrhalis</i> respiratory infections. Rev. Infect. Dis. 9:1140-1149.
SD	4. McLeod, D.T., F. Ahmad, M.J. Croughan, and M.A. Calder. 1986. Bronchopulmonary infection due to <i>M. catarrhalis</i> . Clinical features and therapeutic response. Drugs 31(Suppl.3):109-112.
SD	5. Nicotra, B., M. Rivera, J.I. Luman, and R.J. Wallace. 1986. Arch Intern. Med. 146: 890-893
SD	6. Ninane, G., J. Joly, and M. Krayzman. 1978. Bronchopulmonary infection due to <i>Branhamella catarrhalis</i> : 11 cases assessed by transtracheal puncture. Br.Med.Jr. 1:276-278.



MAR 23 2000
TECH CENTER LIBRARY 150/2900

SD

7. Srinivasan, G., M.J. Raff, W.C. Templeton, C.J. Given, R.C. Graves, and J.C. Mel. 1981. *Branhamella catarrhalis* pneumonia: Report of two cases and review of the literature. *Am. Rev. Respir. Dis.* 123:553-555.

8. West, M., S.L. Berk, and J.K. Smith. 1982. *Branhamella catarrhalis* pneumonia. *South. Med. J.* 75:1021-1023.

9. Brorson, J-E., A. Axelsson, and S.E. Holm. 1976. Studies on *Branhamella catarrhalis* (*Neisseria catarrhalis*) with special reference to maxillary sinusitis. *Scan. J. Infect. Dis.* 8:151-155.

10. Evans, F.O., Jr., J.B. Sydnor, W.E.C. Moore, G.R. Moore, J.L. Manwaring, A.H. Brill, R.T. Jackson, S. Hanna, J.S. Skaar, L.V. Holdeman, G.S. Fitz-Hugh, M.A. Sande, and J.M. Gwaltney, Jr. 1975. Sinusitis of the maxillary antrum. *N. Engl. J. Med.* 293:735-739.

11. Tinkelman, D.G., and H.J. Silk. 1989. Clinical and bacteriologic features of chronic sinusitis in children. *Am. J. Dis. Child.* 143:938-942.

12. Wald, E.R., C. Byers, N. Guerra, M. Casselbrant, and D. Beste. 1989. Subacute sinusitis in children. *J. Pediatr.* 115:28-32.

13. Wald, E.R., G.J. Milmoe, A. Bowen, J. Ledesma-Medina, N. Salamon, and C.D. Bluestone. 1981. Acute maxillary sinusitis in children. *N. Engl. J. Med.* 304:749-754.

14. Christensen, J.J., and B. Bruun. 1985. Bacteremia caused by a beta-lactamase producing strain of *Branhamella catarrhalis*. *Acta Pathol. Microbiol. Immunol. Scand. Sect. B* 93:273-275.

15. Craig, D.B., and P.A. Wehrle. 1983. *Branhamella catarrhalis* septic arthritis. *J. Rheumatol.* 10:985-986.

16. Gray, L.D., R.E. Van Scoy, J.P. Anhalt, and P.K.W. Yu. 1989. Wound infection caused by *Branhamella catarrhalis*. *J. Clin. Microbiol.* 27:818-820.

17. Guthrie, R., K. Bakenhaster, R. Nelson, and R. Woskobnick. 1988. *Branhamella catarrhalis* sepsis: a case report and review of the literature. *J. Infect. Dis.* 158:907-908.

18. Hiroshi Saito, E.J. Anaissie, N. Khardori, and G.P. Bodey. 1988. *Branhamella catarrhalis* septicemia in patients with leukemia. *Cancer* 61:2315-2317.

19. O'Neill, J.H., and P.W. Mathieson. 1987. Meningitis due to *Branhamella catarrhalis*. *Aust. N.Z. J. Med.* 17:241-242.

20. Murphy, T.F. 1989. The surface of *Branhamella catarrhalis*: a systematic approach to the surface antigens of an emerging pathogen. *Pediatr. Infect. Dis. J.* 8:S75-S77.

** 21. Klingman, K.L., and T.F. Murphy. 1994. Purification and characterization of a high-molecular-weight outer membrane protein of *Moraxella* (*Branhamella*) *catarrhalis*. *Infect. Immun.* 62:1150-1155.

22. Helminen, M.E., I. Maciver, J.L. Latimer, J. Klesney-Tait, L.D. Cope, M. Paris, G.H. McCracken, Jr., and E.J. Hansen. 1994. A large, antigenically conserved protein on the surface of *Moraxella catarrhalis* is a target for protective antibodies. *J. Infect. Dis.* 170:867-872.

SD

MAR 22 2000

		23. Aebi, C., I. Maciver, J.L. Latimer, L.D. Cope, M.K. Stevens, S.E. Thomas, G.H. McCracken, Jr., and E.J. McCracken , 1997. A protective epitope of <i>Moraxella catarrhalis</i> is encoded by two different genes. <i>Infect. Immun.</i> 65:4367-4377.
		24. Nixon-George et al. The adjuvant effect of Stearyl Tyrosine on a recombinant subunit hepatitis B surface antigen. (1990), <i>J. Immunology</i> 144:4798-4802.
		25. Wiesmuller (1989), Novel low-molecular weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator, <i>Vaccine</i> 8:29-33.
	**	26. Deres et al. (1989), <i>Nature</i> 342:561.
		27. Lockhoff, O. Glycolipids as Immunomodulators: Synthesis and Properties. 1991. <i>Chem. Int. Ed. Engl.</i> 30:1611-1620.
		28. Tabor and Richardson, 1985, <i>PNAS</i> 82(4):1074-8.
	**	29. Fitzgerald et al, <i>FEMS Immunol. & Med. Microbiol.</i> 18:209-216, 1997.
	**	30. Fitzgerald et al, <i>FEMS Immunol. & Med Microbiol.</i> 23:57-66, 1999.
	**	31. Kyd et al, <i>J. Med. Microbiology</i> , 47:159-168, 1998.
	**	32. Johnson et al, 1997, <i>EMBO J.</i> 10(2):477-488.
	**	33. Benz, I. and Schmidt, M.A., 1992. <i>Mol Microbiol</i> 6:1539-1546.
EXAMINER: SD		DATE CONSIDERED: Sept 01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1038-921 MIS:bh	SERIAL NO. 09/361,619
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<p style="text-align: center;"><i>U.S.P.E. J.C. 39</i></p> <p style="text-align: center;">MAR 02 2001</p> <p style="text-align: center;">PATENT & TRADEMARK OFFICE</p>			
APPLICANT Sheena M. Loosmore et al			
FILING DATE July 27, 1999		GROUP <i>1644-1645</i>	

U.S. PATENT DOCUMENTS

*INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION
							YES NO
<i>SD</i>		WO 00 55191	Sept.21,2000	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>SD</i>		Sasaki, K. et al: "Control mechanism of the 200 kD protein gene expression in Moraxella (Branhamella) catarrhalis". American Society FOR, vol. 99, 1999, page 89

EXAMINER:

*SD*DATE CONSIDERED: *SD - 01*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

RECEIVED

MAR 05 2001

TECH CENTER 1600/200